Skip to main content

Advertisement

SpringerLink
Log in

Influence of TGFB1+869T>C functional polymorphism in non-small cell lung cancer (NSCLC) risk

  • Original Paper
  • Published:
Journal of Cancer Research and Clinical Oncology Aims and scope Submit manuscript

Abstract

Purpose

Lung cancer is the third most common type of cancer in Europe and is the first cause of death by cancer worldwide. Non-small cell lung cancer accounts for 75–85% of all histological types of LC. The transforming growth factor beta 1 is a multifunctional regulatory polypeptide that controls many aspects of cellular function (cellular proliferation, differentiation, migration, apoptosis, immune surveillance). TGFB1+869T>C is a functional polymorphism described in TGFB1 gene and this transition has been associated with higher circulating levels of TGFß1 that may modulate cellular microenvironment and consequently LC development and prognosis.

Methods

We studied TGFB + 869T > C functional polymorphism by allelic discrimination using 7300 real-time polymerase chain reaction system in 305 patients with NSCLC and 380 healthy individuals.

Results

We found an increased risk for C carriers to develop NSCLC, both epidermoid NSCLC and non-epidermoid NSCLC (odds ratio (OR) = 2.03, P < 0.0001, OR = 2.37, P < 0.001 and OR = 1.83, P = 0.001, respectively). TGFB1+869T>C functional polymorphism may influence NSCLC susceptibility with impact in cellular microenvironment.

Conclusions

Our results suggest that individual differences influence the susceptibility to LC and tumoral behavior. This genetic profiling may help define higher risk groups for an individualized chemoprevention strategy and therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Berndt SI, Huang WY, Chatterjee N, Yeager M, Welch R, Chanock SJ, Weissfeld JL, Schoen RE, Hayes RB (2007) Transforming growth factor beta 1 (TGFB1) gene polymorphisms and risk of advanced colorectal adenoma. Carcinogenesis 28:1965–1970

    Article  CAS  PubMed  Google Scholar 

  • Bierie B, Moses H (2006) TGF-b: the molecular Jekyll and Hyde of cancer. Nat Rev 6:506–520

    Article  CAS  Google Scholar 

  • Blobe GC, Schiemann WP, Lodish HF (2000) Role of transforming growth factor ß in human disease. N England J Med 324:1350–1358

    Article  Google Scholar 

  • Cohen V, Khuri FR (2004) Chemoprevention of lung cancer. Curr Opin Pulm Med 10:279–283

    Article  CAS  PubMed  Google Scholar 

  • Colakogullari M, Ulukaya E, Yilmaztepe A, Aymak F, Basturk B, Ursavas A, Oral HB (2008) The involvement of Il-10, IL-6, INF-γ, TNF-α, and TGF-ß gene polymorphisms among Turkish lung cancer patients. Cell Biochem Funct 26:283–290

    Article  CAS  PubMed  Google Scholar 

  • Domagala-Kulawik J, Hoser G, Safianowska A, Grubek-Jaworska H, Chazan R (2006) Elevated TGF-ß1 concentration in bronchoalveolar lavage fluid from patients with primary lung cancer. Arch Immunol Ther Exp 54:143–147

    Article  CAS  Google Scholar 

  • Elliott R, Blobe G (2005) Role of transforming growth factor beta in human cancer. J Clin Oncol 23:2078–2093

    Article  CAS  PubMed  Google Scholar 

  • Ewart-Toland A, Chan JM, Yuan J, Balmain A, Ma J (2004) A gain of function TGFB1 polymorphism may be associated with late stage prostate cancer. Cancer Epidemiol Biomarkers Prev 13:759–764

    CAS  PubMed  Google Scholar 

  • Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P (2007) Estimates of the cancer incidence and mortality in Europe in 2006. Ann Onco 18:581–592

    Article  CAS  Google Scholar 

  • Glick AB (2004) TGFß1, back to the future. Cancer Biol Ther 3:276–283

    Article  CAS  PubMed  Google Scholar 

  • Grainger DJ, Heathcote K, Chiano M, Snieder H, Kemp PR, Metcalfe JC, Carter ND, Spector TD (1999) Genetic control of the circulating concentration of transforming growth factor type beta1. Hum Mol Genet 8:93–97

    Article  CAS  PubMed  Google Scholar 

  • Jin Q, Hemminki K, Grzybowska E, Klaes R, Söderberg M, Zientek H, Rogozinska-Szczepka J, Utracka-Hutka B, Pamula J, Pekala W, Försti A (2004) Polymorphisms and haplotype structures in genes for transforming growth factor ß1 and its receptors in familial and unselected breast cancers. Int J Cancer 112:94–99

    Article  CAS  PubMed  Google Scholar 

  • Jin G, Deng Y, Miao R, Hu Z, Zhou Y, Tan Y, Wang J, Hua Z, Ding W, Wang L, Chen W, Shen J, Wang X, Xu Y, Shen H (2008) TGFB1 and TGFBR2 functional polymorphisms and risk of esophageal squamous cell carcinoma: a case-control analysis in a Chinese population. J Cancer Res Clin Oncol 134:345–351

    Article  CAS  PubMed  Google Scholar 

  • Kang HG, Chae MH, Park JM, Kim EJ, Park JH, Kam S, Cha SI, Kim CH, Park RW, Park SH, Kim YL, Kim IS, Jung TH, Park JY (2006) Polymorphisms in TGF-beta1 gene and the risk of lung cancer. Lung Cancer 52:1–7

    Article  PubMed  Google Scholar 

  • Kang D, Lee KM, Park SK, Berndt SI, Reding D, Chatterjee N, Welch R, Chanock S, Huang W-Y, Hayes RB (2007) Lack of association of transforming growth factor-B1 polymorphisms and haplotypes with prostate cancer risk in the prostate, lung, colorectal, and ovarian trial. Cancer Epidemiol Biomarkers Prev 16:1303–1305

    Article  CAS  PubMed  Google Scholar 

  • Kim WS, Park C, Jung YS, Kim HS, Han J, Park CH, Kim K, Kim J, Shim YM, Park K (1999) Reduced transforming growth factor-ß type II receptor (TGF-beta RII) expression in adenocarcinoma of the lung. Anticancer Res 19:301–306

    CAS  PubMed  Google Scholar 

  • Kirkbride KC, Blobe GC (2003) Inhibiting the TGF-beta signalling pathway as a means of cancer immunotherapy. Expert Opin Biol Ther 3:251–261

    CAS  PubMed  Google Scholar 

  • Kong F, Jirtle RL, Huang DH, Clough RW, Anscher MS (1999) Plasma transforming growth factor-beta1 level before radiotherapy correlates with long term outcome of patients with lung carcinoma. Cancer 86:1712–1719

    Article  CAS  PubMed  Google Scholar 

  • Li Z, Habuchi T, Tsuchiya N, Mitsumori K, Wang L, Ohyama C, Sato K, Kamoto T, Ogawa O, Kato T (2004) Increased risk of prostate cancer and benign prostatic hyperplasia associated with transforming growth factor-beta 1 gene polymorphism at codon 10. Carcinogenesis 25:237–240

    Article  CAS  PubMed  Google Scholar 

  • Marchand L, Haiman CA, van den Berg D, Wilkens LR, Kolonel LN, Henderson BE (2004) T29C polymorphism in the transforming growth factor B1 gene and postmenopausal breast cancer risk: the multiethnic cohort study. Cancer Epidemiol Biomarkers Prev 13:412–415

    PubMed  Google Scholar 

  • Moore LD, Isayeva T, Siegal GP, Ponnazhagan S (2008) Silencing of transforming growth factor-ß1 in situ by RNA interference for breast cancer: implications for proliferation and migration in vitro and metastasis in vivo. Clin Cancer Res 14:4961–4970

    Article  CAS  PubMed  Google Scholar 

  • Nagatake M, Takagi Y, Osada H, Uchida K, Mitsudomi T, Saji S, Shimokata K, Takahashi T, Takahashi T (1996) Somatic in vivo alterations of the DPC4 gene at 18q21 in human lung cancers. Cancer Res 56:2718–2720

    CAS  PubMed  Google Scholar 

  • Park KH, Han SG, Whang YM, Lee HJ, Yoo YD, Lee JW, Shin SW, Kim YH (2006) Single nucleotide polymorphisms of the TGFB1 gene and lung cancer risk in a Korean population. Cancer Genet Cytogenet 169:39–44

    Article  CAS  PubMed  Google Scholar 

  • Prud’homme DJ (2008) Pathobiology of transforming growth factor ß in cancer, fibrosis and immunologic disease, and therapeutic considerations. Lab Invest 87:1077–1091

    Article  Google Scholar 

  • Rich JN, Borton AJ, Wang XF (2001) Transforming growth factor-ß signaling in cancer. Microsc Res Tech 52:363–373

    Article  CAS  PubMed  Google Scholar 

  • Saunier EF, Akhurst RJ (2006) TGF beta inhibition for cancer therapy. Curr Cancer Drug Targets 6:565–578

    Article  CAS  PubMed  Google Scholar 

  • Seifart C, Plagens A, Dempfle A, Clostermann U, Vogelmeier C, von Wichert P, Seifart U (2005) TNF-alpha, TNF-beta, IL-6, and IL-10 polymorphisms in patients with lung cancer. Dis Markers 21:157–165

    CAS  PubMed  Google Scholar 

  • Siegel PM, Massague J (2003) Cytostatic and apoptotic actions of TGF-ß in homeostasis and cancer. Nat Rev Cancer 3:807–820

    Article  CAS  PubMed  Google Scholar 

  • Spira A, Ettinger DS (2004) Multidisciplinary management of lung cancer. N Engl J Med 350:379–392

    Article  CAS  PubMed  Google Scholar 

  • Tang B, de Castro K, Barnes HE, Parks WT, Stewart L, Böttinger EP, Danielpour D, Wakefield LM (1999) Loss of responsiveness of to transforming growth factor beta induces malignant transformation of nontumorigenic rat prostate epithelial cells. Cancer Res 59:4834–4842

    CAS  PubMed  Google Scholar 

  • Teixeira AL, Ribeiro R, Morais A, Lobo F, Fraga A, Pina F, Calais-da-Silva FM, Calais-da-Silva FE, Medeiros R (2009) Combined analysis of EGF+61G>A and TGFB1+869T>C functional polymorphisms in the time to androgen independence and prostate cancer susceptibility. Pharmacogenomics J 9:341–346

    Article  CAS  PubMed  Google Scholar 

  • Uchida K, Nagatake M, Osada H, Yatabe Y, Kondo M, Mitsudomi T, Masuda A, Takahashi T, Takahashi T (1996) Somatic in vivo alterations of the JV18–1 gene at 18q21 in human lung cancers. Cancer Res 56:5583–5585

    CAS  PubMed  Google Scholar 

  • Wei Y-S, Zhu Y-H, Du B, Yang ZH, Liang WB, Lv ML, Kuang XH, Tai SH, Zhao Y, Zhang L (2007) Association of transforming growth factor-β1 gene polymorphisms with genetic susceptibility to nasopharyngeal carcinoma. Clin Chim Acta 380:165–169

    Article  CAS  PubMed  Google Scholar 

  • Yokota M, Ichihara S, Lin TL, Nakashima N, Yamada Y (2000) Association of a T29C polymorphism of the transforming growth factor-beta 1gene with genetic susceptibility to myocardial infarction in Japanese. Circulation 101:2783–2787

    CAS  PubMed  Google Scholar 

Download references

Acknowledgments

We would like to thank the Liga Portuguesa Contra o Cancro—Centro Regional do Norte (Portuguese League Against Cancer); FCT—Fundação para a Ciência e Tecnologia (PTDC/SAU-FCF/71552/2006), Portuguese governmental foundation for science and technology; ALT and RR are a recipients of a Doctoral degree grant from FCT (SFRH/BD/47381/2008, SFRH/BD/30021/2006, respectively).

Conflict of interest statement

The authors disclose any commercial or other associations with acknowledged institutions that might pose a conflict of interest in connection with submitted material.

Author information

Authors and Affiliations

  1. Molecular Oncology GRP-CI, Portuguese Institute of Oncology, Porto Centre, Edifício Laboratórios, 4º piso, Rua Dr. António Bernardino de Almeida, 4200-072, Porto, Portugal

    Ana L. Teixeira, Ana Coelho, Ricardo Ribeiro, Mónica Gomes, Carina Pereira & Rui Medeiros

  2. ICBAS, Abel Salazar Institute for the Biomedical Sciences, University of Porto, Largo Professor Abel Salazar, 4099-003, Porto, Portugal

    Ana L. Teixeira, António Araújo, Ricardo Ribeiro, Mónica Gomes, Carina Pereira & Rui Medeiros

  3. Oncology Department, Portuguese Institute of Oncology, Porto Centre, Rua Dr. António Bernardino de Almeida, 4200-072, Porto, Portugal

    António Araújo

  4. Faculty of Medicine of University of Porto, Alameda professor Hernâni Monteiro, 4200-319, Porto, Portugal

    Ana Coelho

Authors
  1. Ana L. Teixeira
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. António Araújo
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ana Coelho
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ricardo Ribeiro
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Mónica Gomes
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Carina Pereira
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Rui Medeiros
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Rui Medeiros.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Teixeira, A.L., Araújo, A., Coelho, A. et al. Influence of TGFB1+869T>C functional polymorphism in non-small cell lung cancer (NSCLC) risk. J Cancer Res Clin Oncol 137, 435–439 (2011). https://doi.org/10.1007/s00432-010-0896-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00432-010-0896-6

Keywords

Search

Navigation